The evolving regulatory landscape in regenerative medicine

Danielle J. Beetler, Damian N. Di Florio, Ethan W. Law, Chris M. Groen, Anthony J. Windebank, Quinn P. Peterson, De Lisa Fairweather

Research output: Contribution to journalReview articlepeer-review


Regenerative medicine as a field has emerged as a new component of modern medicine and medical research that encompasses a wide range of products including cellular and acellular therapies. As this new field emerged, regulatory agencies like the Food and Drug Administration (FDA) rapidly adapted existing regulatory frameworks to address the transplantation, gene therapy, cell-based therapeutics, and acellular biologics that fall under the broader regenerative medicine umbrella. Where it has not been possible to modify existing regulation and processes, entirely new frameworks have been generated with the intention of providing flexible, forward-facing systems to regulate this rapidly growing field. This review discusses the current state of FDA regulatory affairs in the context of stem cells and extracellular vesicles by highlighting gaps in the current regulatory system and then discussing where regulatory science in regenerative medicine may be headed based on these gaps and the FDA's historical ability to deal with emerging fields. Lastly, we utilize case studies in stem cell and acellular based treatments to demonstrate how regulatory science has evolved in regenerative medicine and highlight the ongoing clinical efforts and challenges of these therapies.

Original languageEnglish (US)
Article number101138
JournalMolecular Aspects of Medicine
StatePublished - Jun 2023


  • Extracellular vesicles
  • Nanomedicine
  • Regenerative medicine
  • Stem cells
  • Translational research

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'The evolving regulatory landscape in regenerative medicine'. Together they form a unique fingerprint.

Cite this